NCT07627568Recruiting
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 30 May 2026
- Start date
- 30 May 2026
- Primary completion date
- 30 May 2027
- Lead sponsor
- University of Freiburg
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07627568
What you commit to
- Study type: Observational
- Planned participants: 20
- From 30 May 2026 to the primary completion date, 30 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- no signed informed consent
Who the study is looking for
- Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements
- Hematological relapse after allo-HCT
- 18 years or older
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Freiburg Mdical Center Coordinator of this site? Confirm its status | Freiburg im Breisgau | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.